PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.44%
EBIT growth below 50% of AGEN's 172.18%. Michael Burry would suspect deeper competitive or cost structure issues.
10.44%
Operating income growth under 50% of AGEN's 166.47%. Michael Burry would be concerned about deeper cost or sales issues.
10.28%
Net income growth under 50% of AGEN's 138.75%. Michael Burry would suspect the firm is falling well behind a key competitor.
12.12%
EPS growth under 50% of AGEN's 136.45%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
10.49%
Diluted EPS growth under 50% of AGEN's 130.69%. Michael Burry would worry about an eroding competitive position or excessive dilution.
2.21%
Share reduction more than 1.5x AGEN's 25.93%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.06%
Negative OCF growth while AGEN is at 313.86%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-28.93%
Negative FCF growth while AGEN is at 306.21%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4997.65%
Negative 10Y OCF/share CAGR while AGEN stands at 1252.08%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
52.56%
Below 50% of AGEN's 348.69%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
56.42%
3Y OCF/share CAGR under 50% of AGEN's 300.49%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-10058.37%
Negative 10Y net income/share CAGR while AGEN is at 383.06%. Joel Greenblatt sees a major red flag in long-term profit erosion.
92.69%
Below 50% of AGEN's 1799.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
51.37%
Below 50% of AGEN's 132.83%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
741.48%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
108.54%
Positive 5Y equity/share CAGR while AGEN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-89.94%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
Negative asset growth while AGEN invests at 80.30%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-40.69%
We have a declining book value while AGEN shows 45.73%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
499.58%
Debt growth far above AGEN's 56.17%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-14.73%
Our R&D shrinks while AGEN invests at 11.38%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
3.54%
SG&A declining or stable vs. AGEN's 11.12%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.